Eurofins Biopharma Products Testing Denmark A/SAktiv

CVR 29428689

Økonomiske nøgletal

76.588.460 kr.+17,8%
Bruttofortjeneste 2025
+8,7%
Gennemsnitlig vækst pr. år 2017–2025
020 mio.40 mio.60 mio.80 mio.20172018201920202021202320242025

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
050 mio.100 mio.20172018201920202021202320242025

Udbytte

foreslået
2025

Foreslået udbytte for regnskabsåret 10.200.000 kr. (100% af årets resultat).

Historik
202510.200.000 kr.
202410.700.000 kr.
20231.000.000 kr.
202110.000.000 kr.
20209.500.000 kr.
20197.000.000 kr.
20185.000.000 kr.
20179.800.000 kr.

Foreslået udbytte for regnskabsåret fra årsrapportens resultatdisponering (udbetales normalt året efter generalforsamlingen).

Selskabsskat

Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet EUROFINS NSC DENMARK A/S.

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Koncernregnskab

2023
Bruttofortjeneste
54.476.694 kr.
Resultat af primær drift
2.995.200 kr.
Årets resultat
1.246.608 kr.
Egenkapital
12.807.444 kr.
Aktiver i alt
64.487.660 kr.
Ansatte
90

Tallene ovenfor på siden gælder selskabet alene (modervirksomheden); koncerntallene omfatter også dattervirksomheder.

Regnskabstal2017–2025
20172018201920202021202320242025
Balance — aktiver
Likvide beholdninger2.951.67906915411.385———
Omsætningsaktiver i alt27.815.41021.637.12222.762.38337.455.85540.060.76335.313.03559.727.82558.276.727
Anlægsaktiver i alt7.655.2307.718.3817.028.5777.422.9419.250.87029.174.62526.921.57122.212.713
Aktiver i alt35.470.64029.355.50329.790.96044.878.79649.311.63364.487.66086.649.39680.489.440
Balance — passiver
Kortfristede gældsforpligtelser22.529.88419.718.25719.150.67222.559.02521.484.84721.233.73760.601.57526.895.796
Langfristede gældsforpligtelser———9.325.5439.277.82930.446.4793.497.55330.606.569
Gældsforpligtelser i alt22.529.88421.366.64519.553.67231.884.56830.762.67651.680.21664.099.12857.502.365
Selskabskapital700.000700.000700.000700.000700.000700.000700.000750.000
Overført resultat2.255.3932.288.8582.537.2882.794.2287.848.95711.107.44411.150.26812.037.075
Årets resultat9.825.9455.033.4657.248.4309.756.94011.554.7291.246.60810.742.82410.230.696
Egenkapital i alt12.755.3937.988.85810.237.28812.994.22818.548.95712.807.44422.550.26822.987.075
Resultatopgørelse
Bruttofortjeneste42.835.91938.294.43141.727.69951.638.63856.810.47054.476.69464.991.26176.588.460
Resultat af primær drift12.869.4676.712.4149.533.34913.184.25514.912.9392.995.20014.686.47714.127.292
EBITDA15.095.8488.944.13411.725.14215.309.19517.310.7566.888.05119.756.87419.003.028
Resultat før skat12.600.5756.458.3379.311.17512.508.23014.830.8781.604.96413.783.63713.151.884
Årets resultat9.825.9455.033.4657.248.4309.756.94011.554.7291.246.60810.742.82410.230.696
Personaleomkostninger27.740.07129.350.29730.002.55736.329.44339.499.71447.588.64345.234.38757.585.432
Af- og nedskrivninger2.226.3812.231.7202.191.7932.124.9402.397.8173.892.8515.070.3974.875.736
Andre nøgletal
Ansatte5764677178907595
Udbytte9.800.0005.000.0007.000.0009.500.00010.000.0001.000.00010.700.00010.200.000

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

Eurofins Biopharma Product Testing Denmark A/S main activities include investigations, laboratory testing and consultancy within the pharmaceutical area and mainly according to the GMP. ​​The Company has in 2025 merged with Eurofins Professional Scientific Services Denmark A/S.

Development in activities and financesThe Company has in 2025 had sufficient staff resources to safeguard stable and qualified services to our customers and expect also for 2026 to be able to attract and sustain a strong team of specialists and key employees. ​​Furthermore, the Company has - together with other companies in the Eurofins Group - invested heavily in development of leader talents. These initiatives together with continued focusing on improvement of products, processes and efficiency mean that Eurofins Biopharma Product Testing Denmark is well positioned for the future on knowledge, capacity and resources. ​​The Company will in 2026 continue its effort to meet customers’ needs by offering a broad portfolio of services, tests and methods and to develop new services as required. ​​In parallel, focus will continue being on reducing our climate impact by reducing energy consumption and by local​production of green energy.

Uddrag af ledelsesberetningen i den seneste årsrapport.

Eurofins Biopharma Products Testing Denmark A/S — cvrprofil.dk